Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

The impact of PEGylation on protein immunogenicity.

Posted by on in 2013
  • Font size: Larger Smaller
  • Hits: 2228
  • Print
Gefen TVaya JKhatib SHarkevich NArtoul FHeller EDPitcovski JAizenshtein E. 2013. Int Immunopharmacol. 15(2):254-259. doi: 10.1016/j.intimp.2012.12.012. [Epub ahead of print]

MIGAL, Galilee Technology Center, P.O. Box 831, Kiryat Shmona 11016, Israel; Department of Animal Sciences, Robert H. Smith Faculty of Agriculture, Food and Environment, Hebrew University, Rehovot 76100, Israel.


Covalent attachment of PEG (PEGylation) is widely used to improve the pharmaceutical properties of therapeutic proteins. The applicability and safety of this method have been proven by the use of various PEGylated pharmaceutical proteins approved by the Food and Drug Administration (FDA). One of the properties attributed to PEGylation is immunogenicity reduction of the PEGylated protein. In this study, the impact of PEGylation on immunogenicity was tested and compared for two proteins (chicken IgY and horse IgG) in two strains of mice (Balb/c and C57BL/6) for two routes of administration (i.v. and i.m.) and two sizes of PEG (5kD and 20kD). The influence of PEG was shown to be inconsistent between the mouse strains and routes of administration, even with the same tested protein. Consequently, immunogenicity reduction by PEGylation cannot be predicted or assumed; it must be tested on an individual case basis.

Copyright © 2012 Elsevier B.V. All rights reserved.

[PubMed - as supplied by publisher]
Last modified on